Merck, Inc.
🇵🇭Philippines
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
Phase 4
Terminated
- Conditions
- Hepatitis C, ChronicHepacivirusHIV Infections
- Interventions
- Biological: Peginterferon alfa-2b (SCH 054031)Drug: Ribavirin (SCH 018908)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT00687544
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT00686725
Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Pegylated Interferon alfa-2bDrug: Ribavirin
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT00686777
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
Phase 3
Completed
- Conditions
- Hepatitis C
- Interventions
- Biological: Pegylated interferon alfa-2bDrug: Ribavirin
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00686517
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
Phase 2
Terminated
- Conditions
- Akathisia, Drug-InducedDyskinesia, Drug-InducedParkinsonian Disorders
- Interventions
- Drug: PlaceboDrug: Preladenant
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT00686699
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00687362
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
Phase 3
Completed
- Conditions
- Hepatitis D, ChronicHepatitis B, Chronic
- Interventions
- Biological: Peginterferon alfa-2b (PegIntron, SCH 54031)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00686790
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Phase 4
Completed
- Conditions
- Fungal InfectionAcute Myelogenous LeukemiaNeutropenia
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT00686543
Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)
- Conditions
- Mycoses
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00686621
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
Phase 2
Completed
- Conditions
- Leukemia, Acute MyeloidMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT00687323
© Copyright 2025. All Rights Reserved by MedPath